Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LGMN | Q99538 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3788743 | 0.78 | ADORA2B (0.38) | ALDH1A1KDM4EGLAKMT2AMAPT | |
| SCHEMBL12775695 | 0.77 | ALDH1A1 (0.33) | ALDH1A1LGMNLMNA | |
| SCHEMBL3521446 | 0.77 | GAA (0.41) | ALDH1A1KMT2AMEN1MAPTHPGD | |
| SCHEMBL14886983 | 0.76 | ALDH1A1 (0.45) | AOC3ALDH1A1KDM4EGLAKMT2A | |
| SCHEMBL22016882 | 0.73 | KDM5A (0.35) | KDM5AALDH1A1KDM4E | |
| SCHEMBL12926006 | 0.72 | KDM5A (0.34) | KDM5A | |
| SCHEMBL13024710 | 0.71 | ATAD2 (0.39) | ALDH1A1KDM4EHPGDLGMNLMNA | |
| SCHEMBL13024384 | 0.70 | ADORA2A (0.41) | ALDH1A1KDM4EHPGDLGMNLMNA | |
| SCHEMBL19530909 | 0.68 | ALDH1A1 (0.47) | ALDH1A1KDM4EGLAKMT2AMEN1 | |
| SCHEMBL13492907 | 0.68 | ADORA2A (0.36) | AOC3ALDH1A1KDM4EGLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20130079383-A1 | Lipid Compounds Targeting VLA-4 | ARROWHEAD RESEARCH CORPORATION (US) | 2013-03-28 | — | — | US | disclosed |
| EP-0647231-A1 | N-SUBSTITUTED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AG (DE) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000458-A1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | KDM5A 2224/4885AOC3 3986/4885ALDH1A1 2009/4885 |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | KDM5A 3004/4885AOC3 4477/4885ALDH1A1 823/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | KDM5A 2534/4885AOC3 4401/4885ALDH1A1 791/4885 |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KDM5A 2386/4885AOC3 3603/4885ALDH1A1 476/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KDM5A 2386/4885AOC3 3603/4885ALDH1A1 476/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | KDM5A 2656/4885AOC3 4258/4885ALDH1A1 838/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | KDM5A 3004/4885AOC3 4477/4885ALDH1A1 823/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | KDM5A 2386/4885AOC3 3603/4885ALDH1A1 476/4885 |
| US-20130079383-A1 | Lipid Compounds Targeting VLA-4 | LPAR4, ASGR1, VCAM1 | KDM5A 4066/4885AOC3 4634/4885ALDH1A1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.